BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 41 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,588 | +830.6% | 46,800 | +836.0% | 0.05% | +1200.0% |
Q2 2023 | $493 | -91.7% | 5,000 | -91.5% | 0.00% | -94.2% |
Q1 2023 | $5,967 | -99.9% | 58,800 | +31.5% | 0.07% | +130.0% |
Q3 2020 | $4,704,000 | +284.0% | 44,720 | +347.2% | 0.03% | +200.0% |
Q2 2020 | $1,225,000 | +16.7% | 10,000 | 0.0% | 0.01% | 0.0% |
Q1 2020 | $1,050,000 | -0.8% | 10,000 | 0.0% | 0.01% | 0.0% |
Q4 2019 | $1,059,000 | +7.5% | 10,000 | 0.0% | 0.01% | +25.0% |
Q3 2019 | $985,000 | -32.4% | 10,000 | -28.6% | 0.01% | -20.0% |
Q2 2019 | $1,457,000 | +42.0% | 14,000 | +40.0% | 0.01% | +11.1% |
Q1 2019 | $1,026,000 | +2.9% | 10,000 | 0.0% | 0.01% | 0.0% |
Q4 2018 | $997,000 | -48.2% | 10,000 | -44.4% | 0.01% | -35.7% |
Q3 2018 | $1,923,000 | +5.5% | 18,000 | 0.0% | 0.01% | -12.5% |
Q2 2018 | $1,823,000 | +7.9% | 18,000 | 0.0% | 0.02% | +14.3% |
Q1 2018 | $1,690,000 | +69.7% | 18,000 | +80.0% | 0.01% | +55.6% |
Q4 2017 | $996,000 | -34.5% | 10,000 | -33.3% | 0.01% | -30.8% |
Q3 2017 | $1,520,000 | – | 15,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 16,298,000 | $15,340,000 | 1.64% |
ZAZOVE ASSOCIATES LLC | 25,540,000 | $24,103,000 | 1.55% |
PIER 88 INVESTMENT PARTNERS LLC | 3,030,000 | $2,844,000 | 1.36% |
Jabre Capital Partners S.A. | 5,500,000 | $5,184,000 | 1.12% |
Sonora Investment Management, LLC | 7,100,000 | $6,681,214,000 | 1.06% |
ADVENT CAPITAL MANAGEMENT /DE/ | 43,256,000 | $40,793,000 | 0.80% |
Opera Trading Capital | 10,000,000 | $9,370,000 | 0.72% |
AQR Arbitrage LLC | 52,575,000 | $49,486,000 | 0.57% |
Neuberger Berman Group LLC | 5,000,000 | $469,375,000 | 0.54% |
CQS Cayman LP | 12,000,000 | $11,322,000 | 0.52% |